These pathways are closely associated with hormone receptor signaling, oncogenic transcriptional regulation, and cellular proliferation, suggesting that O-desmethyltramadol may exert its effects in hormone receptor-positive breast cancer cells by modulating growth factor signaling and oncogene regulation. Here, NR4A1 is linked to breast carcinoma.